CEP-1347
Identification
- Generic Name
- CEP-1347
- DrugBank Accession Number
- DB05403
- Background
CEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons prior to and after transplantation.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 615.762
Monoisotopic: 615.186162561 - Chemical Formula
- C33H33N3O5S2
- Synonyms
- Not Available
Pharmacology
- Indication
Investigated for use/treatment in asthma and parkinson's disease.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
CEP-1347, an orally active molecule, is a selective and potent inhibitor of the stress-activated protein kinase pathway, an intracellular signaling pathway that is an essential component of the stress response leading to neuronal death. In-vitro cell culture systems and in-vivo mouse and non-human primate models of Parkinson's disease have shown that CEP-1347 protects dopamine neurons in the substantia nigra, the area of the brain affected by Parkinson's disease.
Target Actions Organism UMitogen-activated protein kinase 12 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as indolocarbazoles. These are polycyclic aromatic compounds containing an indole fused to a carbazole.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Indoles and derivatives
- Sub Class
- Carbazoles
- Direct Parent
- Indolocarbazoles
- Alternative Parents
- Pyrrolo[2,3-a]carbazoles / Pyrroloindoles / Isoindolones / Indoles / Benzenoids / Tetrahydrofurans / Heteroaromatic compounds / Peroxycarboxylic acids and derivatives / Pyrroles / Lactams show 13 more
- Substituents
- Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Carboxylic acid salt / Dialkylthioether / Heteroaromatic compound / Hydrocarbon derivative show 24 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 200HA2LIMK
- CAS number
- Not Available
- InChI Key
- WMBUVOLZSWTKMP-KQFGJPIXSA-N
- InChI
- InChI=1S/C33H33N3O5S2/c1-5-42-15-17-7-9-23-19(11-17)27-28-21(14-34-31(28)37)26-20-12-18(16-43-6-2)8-10-24(20)36-30(26)29(27)35(23)25-13-22(32(38)41-39-4)33(36,3)40-25/h7-12,22,25H,5-6,13-16H2,1-4H3,(H,34,37)/t22-,25+,33+/m1/s1
- IUPAC Name
- methyl (15S,16S,18S)-10,23-bis[(ethylsulfanyl)methyl]-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1,6,8(13),9,11,20(25),21,23,26-nonaene-16-carboperoxoate
- SMILES
- [H][C@@]12C[C@H](C(=O)OOC)[C@](C)(O1)N1C3=C(C=C(CSCC)C=C3)C3=C4CNC(=O)C4=C4C5=C(C=CC(CSCC)=C5)N2C4=C13
References
- General References
- Bozyczko-Coyne D, O'Kane TM, Wu ZL, Dobrzanski P, Murthy S, Vaught JL, Scott RW: CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. J Neurochem. 2001 May;77(3):849-63. [Article]
- External Links
- PubChem Compound
- 133005
- PubChem Substance
- 175426995
- ChemSpider
- 117379
- ZINC
- ZINC000103589452
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2, 3 Terminated Treatment Parkinson's Disease (PD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0111 mg/mL ALOGPS logP 5.35 ALOGPS logP 6.26 Chemaxon logS -4.8 ALOGPS pKa (Strongest Acidic) 13.39 Chemaxon pKa (Strongest Basic) -1.5 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 83.72 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 171.22 m3·mol-1 Chemaxon Polarizability 23.23 Å3 Chemaxon Number of Rings 8 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9693 Blood Brain Barrier + 0.6995 Caco-2 permeable - 0.5691 P-glycoprotein substrate Substrate 0.6925 P-glycoprotein inhibitor I Inhibitor 0.5838 P-glycoprotein inhibitor II Non-inhibitor 0.9543 Renal organic cation transporter Non-inhibitor 0.7471 CYP450 2C9 substrate Non-substrate 0.8371 CYP450 2D6 substrate Non-substrate 0.8243 CYP450 3A4 substrate Substrate 0.7203 CYP450 1A2 substrate Non-inhibitor 0.6332 CYP450 2C9 inhibitor Non-inhibitor 0.5752 CYP450 2D6 inhibitor Non-inhibitor 0.8831 CYP450 2C19 inhibitor Non-inhibitor 0.5698 CYP450 3A4 inhibitor Inhibitor 0.6903 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.626 Ames test Non AMES toxic 0.6308 Carcinogenicity Non-carcinogens 0.744 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.8432 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9963 hERG inhibition (predictor II) Non-inhibitor 0.5125
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 251.09453 predictedDeepCCS 1.0 (2019) [M+H]+ 253.20126 predictedDeepCCS 1.0 (2019) [M+Na]+ 259.11404 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protein serine/threonine kinase activity
- Specific Function
- Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK12 is one of the four p38 MAPKs which play an important role in the cascades of cellu...
- Gene Name
- MAPK12
- Uniprot ID
- P53778
- Uniprot Name
- Mitogen-activated protein kinase 12
- Molecular Weight
- 41939.84 Da
Drug created at November 18, 2007 18:24 / Updated at June 12, 2020 16:52